Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone

https://www.globenewswire.com/news-release/2019/09/24/1919952/0/en/Catalent-and-Minerva-Neurosciences-Enter-Commercial-Supply-Agreement-for-Schizophrenia-Drug-Roluperidone.html

Under the terms of the agreement, Catalent will manufacture and package the finished dose form of the drug at its facility in Schorndorf, Germany.

2 Likes